3eb0d2e3
2021-12-26
Ok
Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698565331,"tweetId":"698565331","gmtCreate":1640469424390,"gmtModify":1640469424578,"author":{"id":3583621807888930,"idStr":"3583621807888930","authorId":3583621807888930,"authorIdStr":"3583621807888930","name":"3eb0d2e3","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698565331","repostId":1130212885,"repostType":4,"repost":{"id":"1130212885","pubTimestamp":1640397757,"share":"https://www.laohu8.com/m/news/1130212885?lang=&edition=full","pubTime":"2021-12-25 10:02","market":"us","language":"en","title":"Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1130212885","media":"Renaissance Capital","summary":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,","content":"<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.</p>\n<p>The Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.<i>Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.</i></p>\n<p>TC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.</p>\n<p>TC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:02 GMT+8 <a href=https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89799/Scottish-biotech-TC-BioPharm-lowers-deal-size-by-40-adds-warrants-ahead-of-","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130212885","content_text":"TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday.\nThe Holytown, UK-based company now plans to raise $30 million by offering 3.8 million ADSs at $8. The company is also offering 3.8 million warrants to purchase ADSs at $8, each with an exercise price of $10. The company had previously filed to offer 6.3 million shares at a range of $7 to $9. At the revised price, TC BioPharm Holdings will raise -40% less in proceeds than previously anticipated.Because the company is now offering warrants, TC BioPharm is no longer eligible for tracking and will be excluded from Renaissance Capital's stats.\nTC BioPharm (TCB) is focused on developing novel immunotherapies based on its proprietary allogeneic gamma-delta T cell (GD-T) platform. The company's Omnimmune program is expected to enter Phase 2-into-pivotal (Phase 3) trials in the 4Q21 for the treatment of acute myeloid leukemia (AML). The company plans to conduct similar trials for AML in the US following an application to the FDA in the 1H22. TCB is also developing a GD-T therapy for the treatment of COVID-19, with trials expected to start in the 4Q21, and genetically modified CAR-T therapies for solid cancers.\nTC BioPharm Holdings was founded in 2013 and booked $3 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol TCBP. EF Hutton is the sole bookrunner on the deal.","news_type":1},"isVote":1,"tweetType":1,"viewCount":860,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698565331"}
精彩评论